Category: Science

JDRF New Logo

JDRF Funded Researchers Test Topical Drug to Treat Diabetic Macular Edema

The Juvenile Diabetes Research Foundation (JDRF) announced that researchers at the Wilmer Eye Institute of Johns Hopkins University School of Medicine in Maryland completed a multicenter human clinical trial treating diabetic macular edema with mecamylamine, a topical drug developed by the biotech company CoMentis, Inc. Funding for the study was provided by JDRF through its Industry Drug Development Partnership program...
0 Shares
Diamyd_logo

FDA Grants Diamyd Medical´s Diamyd Orphan Drug Designation

Diamyd Medical announced the Food and Drug Administration (FDA) granted its type 1 diabetes drug candidate Diamyd® Orphan Drug Designation. Orphan drugs qualify for several incentives including a seven-year period of market exclusivity in the US...
0 Shares

What is LADA?

A form of diabetes characterized by age, a lack of family history of type 2, a gradual increase in insulin requirements, positive antibodies, and decreasing ability to make insulin...
0 Shares
JDRF New Logo

European Artificial Pancreas On The Way

According to a JDRF press release, a consortium of academic and industrial partners has announced a collaboration called AP@home that aims to develop an artificial pancreas which would allow automated glucose control for people with insulin treated diabetes. In the first phase of the AP@home project, currently available AP algorithms will be tested with CGM (continuous glucose monitoring) systems and insulin pumps...
0 Shares
Diamyd_logo

Diamyd US Phase III study of Type 1 Drug Well on the Way

Diamyd Medical announced that 100 patients are now enrolled in the company's US Phase III study called DiaPrevent at 33 diabetes centers throughout the USA and more sites are to be added. The study will include 320 children and adolescents between 10 and 20 years of age, recently diagnosed with type 1 diabetes....
0 Shares
Amylin logo

Amylin and Takeda Advance Development of New Obesity Treatment

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that following positive phase 2 study results in a new obesity treatment, they will advance towards phase 3 development of a combination treatment for obesity which includes pramlintide (an analog of the natural hormone amylin) and metreleptin (an analog of the natural hormone leptin)...
0 Shares

Dolphin ability to switch on and off diabetes could lead to human cure

Researchers found that dolphins can induce diabetes when there is little food around and turn it off when food is abundant, according to Telegraph. They believe this is a unique ability in the animal kingdom and results from the dolphin’s need to maintain high blood sugar levels to feed its big brain....
0 Shares